People with type 2 diabetes (T2D) fracture more often than non-diabetic individuals despite normal-to-high areal bone mineral density (BMD). In the Rotterdam Study, Oei and colleagues (2013) showed that this paradox tracks glycemic control: participants with inadequately controlled T2D (HbA1c at or above 7.5%, derived from fructosamine) had higher BMD and thicker femoral cortices in narrower bones yet a 47-62% higher fracture risk, while adequately controlled participants fractured at non-diabetic rates. The problem asks for the causal pathway behind this observation: which candidate mechanisms - cortical porosity, microcrack accumulation, advanced glycation end-product (AGE) collagen cross-linking, altered osteoblast/osteoclast function, and changes in the insulin-IGF-I axis - actually produce impaired bone material quality under chronic hyperglycemia, how defects develop over disease duration, and whether improving long-term glycemic control (or remodeling-activating therapy) prevents or reverses the material-level defects and reduces fracture incidence.

Background

Type 2 diabetes mellitus (T2D) is a disorder of chronically elevated blood glucose (hyperglycemia) arising from insulin resistance and failing insulin secretion. Bone mineral density (BMD), measured by dual-energy X-ray absorptiometry (DXA), is the standard clinical proxy for bone strength, yet T2D patients fracture at higher rates than non-diabetic people at any given BMD - the so-called diabetes bone paradox. This implies a defect in bone 'quality': properties of bone not captured by DXA, such as microarchitecture, cortical geometry, and the material behavior of the bone matrix itself.

Oei et al. (2013), analyzing 4,135 participants of the population-based Rotterdam Study (mean follow-up 12.2 years), made the observation this problem grows out of. They classified 420 T2D participants by glycemic control using HbA1c (glycated hemoglobin, a time-averaged glucose marker) reconstructed from fructosamine (a glycated serum protein reflecting roughly the prior 3-4 months): adequately controlled diabetes (ACD, HbA1c below 7.5%), inadequately controlled diabetes (ICD, HbA1c at or above 7.5%), and no diabetes (ND). Hip structural analysis of DXA scans showed that the ICD group had 1.1-5.6% higher BMD, 4.6-5.6% thicker femoral cortices, and 1.2-1.8% narrower femoral necks. Despite these apparently 'strong' bones, the ICD group had a 47-62% higher fracture risk than ND (hazard ratio 1.47, 95% CI 1.12-1.92) and ACD (1.62, 1.09-2.40), whereas ACD participants fractured at rates similar to ND. Because baseline HbA1c came from fructosamine and age at diabetes onset was unknown, the study could not address how long hyperglycemia must act before material-level damage appears.

The authors postulated that fragility in these dense bones results from impaired bone repair: accumulation of microcracks and/or cortical porosity (small voids in the compact outer shell of bone) that reduce strength without lowering DXA BMD, consistent with high-resolution peripheral quantitative CT (HR-pQCT; a 3D imaging technique resolving cortical and trabecular microarchitecture at the forearm and shin) findings of over 50% higher cortical porosity at the radius in T2D (Burghardt et al. 2010). Candidate mechanisms they named include: nonenzymatic collagen cross-linking by advanced glycation end products (AGEs, glucose-derived modifications such as pentosidine that stiffen and embrittle the collagen matrix and had already been linked to fracture risk in T2D by Schwartz et al. 2009); compromised osteoblast (bone-forming) and osteoclast (bone-resorbing) cell function, producing the low-turnover state documented in diabetes; and altered insulin-IGF-I (insulin-like growth factor I) signaling, which normally exerts anabolic effects on bone and periosteal expansion. The only randomized evidence available at the time - the ACCORD trial's fracture analysis (Schwartz et al. 2012), comparing intensive versus standard glycemic control over a mean follow-up of about 3.8 years - found no difference in fracture or fall rates, too short to exclude long-term skeletal benefits. Reviews of the field before and since (Napoli et al. 2017; Cavati et al. 2023; Leungsuwan and Chandran 2024) assemble these mechanisms as plausible and partially evidenced, but note that causal attribution to chronic hyperglycemia, and any intervention consequence, remains unproven - while an epidemiological literature (Naderpour et al. 2026, meta-analysis of over 13 million participants) has confirmed the elevated site-specific fracture risk of T2D across populations.

Problem Statement

Establish the causal pathway by which chronic hyperglycemia produces skeletal fragility in type 2 diabetes despite normal-to-high bone mineral density, and determine whether that pathway is modifiable. Concretely, on the basis defined by Oei et al. (2013) and the subsequent literature: (1) determine which of the hypothesized mechanisms - cortical porosity, microcrack accumulation from impaired repair, nonenzymatic collagen cross-linking by advanced glycation end products, altered osteoblast and osteoclast function, and altered insulin-IGF-I axis signaling - actually cause the impaired bone material quality associated with inadequately controlled diabetes; (2) establish the temporal relationship between duration and degree of hyperglycemic exposure and the development of the material-level defects, which the source could not address because HbA1c was derived from fructosamine and age at diabetes onset was unknown; (3) determine whether improving long-term glycemic control prevents or reverses the material-level defects and reduces fracture incidence over the long term; and (4) test the generalizability of the glycemic-control-related skeletal findings beyond the original European cohort, beyond the femoral neck, and with BMD/glycemic classifications based on directly measured HbA1c.

References

  1. Oei, Ling; Zillikens, M. Carola; Dehghan, Abbas; Buitendijk, Gabriëlle H.S.; Castaño-Betancourt, Martha C.; Estrada, Karol; Stolk, Lisette; Oei, Edwin H.G.; van Meurs, Joyce B.J.; Janssen, Joseph A.M.J.L.; Hofman, Albert; van Leeuwen, Johannes P.T.M.; Witteman, Jacqueline C.M.; Pols, Huibert A.P.; Uitterlinden, André G.; Klaver, Caroline C.W.; Franco, Oscar H.; Rivadeneira, Fernando (2013). High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control. Diabetes Care 36(6):1619-1628. doi:10.2337/dc12-1188, https://doi.org/10.2337/dc12-1188
  2. Schwartz, Ann V.; Garnero, Patrick; Hillier, Teresa A.; Sellmeyer, Deborah E.; Strotmeyer, Elsa S.; Feingold, Kenneth R.; Resnick, Helaine E.; Tylavsky, Frances A.; Black, Dennis M.; Cummings, Steven R.; Harris, Tamara B.; Bauer, Douglas C. (2009). Pentosidine and Increased Fracture Risk in Older Adults with Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism 94(7):2380-2386. doi:10.1210/jc.2008-2498, https://doi.org/10.1210/jc.2008-2498
  3. Burghardt, A-J.; Issever, A.S.; Schwartz, A.V.; Davis, K.A.; Masharani, U.; Majumdar, S.; Link, T.M. (2010). High-Resolution Peripheral Quantitative Computed Tomographic Imaging of Cortical and Trabecular Bone Microarchitecture in Patients with Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology & Metabolism 95(11):5045-5055. doi:10.1210/jc.2010-0226, https://doi.org/10.1210/jc.2010-0226
  4. Schwartz, Ann V.; Margolis, Karen L.; Sellmeyer, Deborah E.; Vittinghoff, Eric; Ambrosius, Walter T.; Bonds, Denise E.; Josse, Robert G.; Schnall, Adrian M.; Simmons, Debra L.; Hue, Trisha F.; Palermo, Lisa; Hamilton, Bruce P.; Green, Jennifer B.; Atkinson, Hal H.; O'Connor, Patrick J.; Force, Rex W.; Bauer, Douglas C. (2012). Intensive Glycemic Control Is Not Associated With Fractures or Falls in the ACCORD Randomized Trial. Diabetes Care 35(7):1525-1531. doi:10.2337/dc11-2184, https://doi.org/10.2337/dc11-2184
  5. Napoli, Nicola; Chandran, Manju; Pierroz, Dominique D.; Abrahamsen, Bo; Schwartz, Ann V.; Ferrari, Serge L.; IOF Bone and Diabetes Working Group (2017). Mechanisms of diabetes mellitus-induced bone fragility. Nature Reviews Endocrinology 13(4):208-219. doi:10.1038/nrendo.2016.153, https://doi.org/10.1038/nrendo.2016.153
  6. de Waard, E.A.C.; de Jong, J.J.A.; Koster, A.; Savelberg, H.H.C.M.; van Geel, T.A.; Houben, A.J.H.M.; Schram, M.T.; Dagnelie, P.C.; van der Kallen, C.J.; Sep, S.J.S.; Stehouwer, C.D.A.; Schaper, N.C.; Berendschot, T.T.J.M.; Schouten, J.S.A.G.; Geusens, P.P.M.M.; van den Bergh, J.P.W. (2018). The association between diabetes status, HbA1c, diabetes duration, microvascular disease, and bone quality of the distal radius and tibia as measured with high-resolution peripheral quantitative computed tomography - The Maastricht Study. Osteoporosis International 29(12):2725-2738. doi:10.1007/s00198-018-4678-3, https://doi.org/10.1007/s00198-018-4678-3
  7. Vavanikunnel, Janina; Charlier, Sarah; Becker, Claudia; Schneider, Cornelia; Jick, Susan S.; Meier, Christoph R.; Meier, Christoph (2019). Association Between Glycemic Control and Risk of Fracture in Diabetic Patients: A Nested Case-Control Study. Journal of Clinical Endocrinology & Metabolism 104(5):1645-1654. doi:10.1210/jc.2018-01879, https://doi.org/10.1210/jc.2018-01879
  8. Andrade, Vicente F.C.; Chula, Domingos C.; Sabbag, Fábio P.; Cavalheiro, Daniel D. da S.; Bavia, Lorena; Ambrósio, Altair Rogério; da Costa, Cleber Rafael V.; dos Reis, Lucène M.; Borba, Victória Z.C.; Aguiar Moreira, Carolina (2020). Bone Histomorphometry in Young Patients With Type 2 Diabetes is Affected by Disease Control and Chronic Complications. Journal of Clinical Endocrinology & Metabolism 105(2):506-514. doi:10.1210/clinem/dgz070, https://doi.org/10.1210/clinem/dgz070
  9. Charlier, Sarah; Vavanikunnel, Janina; Becker, Claudia; Jick, Susan S.; Meier, Christoph; Meier, Christoph R. (2020). Antidiabetic Treatment, Level of Glycemic Control, and Risk of Fracture in Type 2 Diabetes: a Nested, Case-Control Study. Journal of Clinical Endocrinology & Metabolism 106(2):554-566. doi:10.1210/clinem/dgaa796, https://doi.org/10.1210/clinem/dgaa796
  10. Cavati, Guido; Pirrotta, Filippo; Merlotti, Daniela; Ceccarelli, Elena; Calabrese, Marco; Gennari, Luigi; Mingiano, Christian (2023). Role of Advanced Glycation End-Products and Oxidative Stress in Type-2-Diabetes-Induced Bone Fragility and Implications on Fracture Risk Stratification. Antioxidants 12(4):928. doi:10.3390/antiox12040928, https://doi.org/10.3390/antiox12040928
  11. Emerzian, Shannon R.; Johannesdottir, Fjola; Yu, Elaine W.; Bouxsein, Mary L. (2024). Use of noninvasive imaging to identify causes of skeletal fragility in adults with diabetes: a review. JBMR Plus 8(2). doi:10.1093/jbmrpl/ziae003, https://doi.org/10.1093/jbmrpl/ziae003
  12. Ghatan, Samuel; Koromani, Fjorda; Trajanoska, Katerina; van Velsen, Evert F.S.; Kavousi, Maryam; Zillikens, M. Carola; Medina-Gomez, Carolina; Oei, Ling; Rivadeneira, Fernando (2024). Evaluating the relationship between glycemic control and bone fragility within the UK Biobank: observational and one-sample Mendelian randomization analyses. JBMR Plus 8(11). doi:10.1093/jbmrpl/ziae126, https://doi.org/10.1093/jbmrpl/ziae126
  13. Leungsuwan, David Suphadetch; Chandran, Manju (2024). Bone Fragility in Diabetes and its Management: A Narrative Review. Drugs 84(9):1111-1134. doi:10.1007/s40265-024-02078-5, https://doi.org/10.1007/s40265-024-02078-5
  14. Ojo, Omorogieva; Onilude, Yemi; Brooke, Joanne; Apau, Victoria; Kazangarare, Ivy; Ojo, Osarhumwese (2025). The Effect of Type 2 Diabetes on Bone Quality: A Systematic Review and Meta-Analysis of Cohort Studies. International Journal of Environmental Research and Public Health 22(6):910. doi:10.3390/ijerph22060910, https://doi.org/10.3390/ijerph22060910
  15. Ikram, Mohammad Arshad; Gnanou, Justin Vijay; Chong, Chin Chai; Ahmed, Nisar; Letchumenan, Shobna Sai; Fithri, Zairul-Nizam Zainol (2025). Association between haemoglobin A1c level and hip fracture risk in type 2 diabetes patients: A systematic review and meta-analysis. Journal of Clinical Orthopaedics and Trauma 67:103040. doi:10.1016/j.jcot.2025.103040, https://doi.org/10.1016/j.jcot.2025.103040
  16. Hikichi, Toshifumi; Kimura, Kumi; Munesue, Seiichi; Oshima, Yu; Harashima, Ai; Hamada, Tomo; Shimokawa, Kanu; Fushitani, Yuki; Goto, Hisanori; Tsuchiya, Hiroyuki; Demura, Satoru; Matsubara, Hidenori; Yamamoto, Yasuhiko (2025). Scavenging methylglyoxal improves bone quality and defect healing in diabetic mice. Bone Reports 27:101883. doi:10.1016/j.bonr.2025.101883, https://doi.org/10.1016/j.bonr.2025.101883
  17. Taskin Kursun, Sevdenur; Imre, Eren; Gogas Yavuz, Dilek (2026). Advanced glycation end-products and sclerostin are elevated across diabetes phenotypes and associated with vertebral fractures in type 2 diabetes. BMC Endocrine Disorders 26(1):145. doi:10.1186/s12902-026-02254-6, https://doi.org/10.1186/s12902-026-02254-6
  18. Naderpour, Sara; Gillies, Clare; O'Riordan, Paul; Fahimfar, Noushin; Karimi, Zahra; Khoramdad, Malihe; Khavere, Sonia; Kundu, Monica; Khunti, Kamlesh; Gharibzadeh, Safoora (2026). Association between type 2 diabetes and site-specific fracture risk: A systematic review and meta-analysis of cohort studies including over 13 million participants. Diabetic Medicine 43(5). doi:10.1111/dme.70276, https://doi.org/10.1111/dme.70276